IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease.
Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the development of novel ADCs with improved plasma stability and reduced systemic toxicity is critically needed.
Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease.
In recognition of the fact that diversity, equity and inclusion are necessary prerequisites for precision medicine, the European Academy of Neurology announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24.
Researchers from Sagittide Therapeutics Co. Ltd. and Shanghai Jiao Tong University have presented results of early studies with a novel MUC1-C-targeted near-infrared imaging agent – SAG-602 – for fluorescence-guided surgery of cancer.
Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A. Inno-8 was characterized in vitro alone or in combination with hemostatic agents used for treating hemophilia A.
MYC is a key regulator of RNA Polymerase I (Pol I) transcription, promoting rRNA synthesis both directly and indirectly. MYC overexpression is common in many cancer types, where it drives increased ribosome biogenesis to support uncontrolled cell growth and proliferation.
Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.
MYB is an oncogenic transcription factor that is often aberrantly expressed in hematologic malignancies, mostly in acute myeloid leukemia (AML). Rgenta Therapeutics Inc. recently presented data for RGT-61159, a potent and selective MYB inhibitor compound that demonstrated cell killing across a panel of MYB-overexpressing leukemic cell lines.
Bispecific antibodies mimicking coagulation factor VIIIa (FVIIIa) have yielded successful results in the treatment of hemophilia A, but there remain some issues in regard to their production.
RSS
